2024/08/20 by Hidetaka Matsumoto, Junki Hoshino, Saki Numaga +3 · 1 citation
paper · doi:10.1007/s10384-024-01107-w
crossref issued 2024/08/20 · crossref published 2024/08/20 · crossref published-online 2024/08/20 · crossref created 2024/08/20 · crossref published-print 2024/09/01 · crossref deposited 2024/09/23 · crossref indexed 2026/07/31
Abstract Purpose To evaluate short-term outcomes of intravitreal injection of aflibercept 8 mg for neovascular age-related macular degeneration (nAMD). Study design Retrospective, interventional case series. Methods We retrospectively studied 35 eyes of 34 consecutive patients with nAMD, assessing best-corrected visual acuity (BCVA), foveal thickness (FT), and central choroidal thickness (CCT) before and 4 weeks after the initial intravitreal dose of aflibercept 8 mg. The rate of achieving a dry macula and the incidence of intraocular inflammation (IOI) at week 4 were also determined. Results BCVA showed significant improvement, with significant reductions in FT and CCT 4 weeks after the initial injection of aflibercept 8 mg (all P Conclusions Intravitreal aflibercept 8 mg appears to be effective for improving visual acuity and ameliorating exudative changes in eyes with nAMD. However, special attention should be given to the potential development of IOI associated with retinal vasculitis.